Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | GFER | P55789 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918905 | 0.98 | CHKA (0.39) | HPGDCYP1A2CYP2C19CYP2C9CHKA | |
| SCHEMBL2067060 | 0.94 | CHKA (0.34) | HPGDCYP1A2CYP2C19CYP2C9CHKA | |
| SCHEMBL3547725 | 0.81 | AR (0.35) | MAPTALDH1A1HSD17B10HIF1ACNR2 | |
| SCHEMBL526372 | 0.81 | PLD1 (0.44) | CYP1A2MAPK1TDP1KDM4EALDH1A1 | |
| SCHEMBL933508 | 0.81 | HTR3A (0.42) | CYP1A2KDM4EALDH1A1 | |
| SCHEMBL14931430 | 0.77 | PDE10A (0.36) | HPGDCYP2C19TSHRALDH1A1HSD17B10 | |
| SCHEMBL15415434 | 0.75 | CYP2C19 (0.30) | CYP2C19HIF1A | |
| SCHEMBL14931280 | 0.74 | VNN1 (0.35) | HPGDCYP1A2CYP2C19CYP2C9MAPK1 | |
| SCHEMBL15416277 | 0.74 | PLD1 (0.39) | CYP1A2MAPK1TDP1KDM4EALDH1A1 | |
| SCHEMBL12468806 | 0.74 | OGA (0.38) | TSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | claimed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | claimed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | claimed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | claimed |
| JP-4748912-B2 | — | — | 2011-08-17 | — | — | JP | claimed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | claimed |
| EP-2134713-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | claimed |
| US-6914122-B2 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION (US) | 2005-07-05 | — | — | US | claimed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | claimed |
| US-6646010-B2 | Enzyme inhibitors such as N(3-benzyloxycarbonylamino-2-hydroxy -4-phenylbutyl)-N-isoamylamine, used for prophylaxis of viral diseases and infections; lymphadenopathy associated virus | G. D. SEARLE & CO. | 2003-11-11 | — | — | US | claimed |
| EP-1274724-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES | SCHERING CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION | 2002-02-07 | — | — | US | claimed |
| WO-2001081325-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES | SCHERING CORPORATION (US) | 2001-11-01 | — | — | WO | claimed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HPGD 2045/4885CYP1A2 532/4885CYP2C19 799/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | HPGD 2158/4885CYP1A2 628/4885CYP2C19 3619/4885 |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | PRSS3, HPN, DPP3 | HPGD 2555/4885CYP1A2 2058/4885CYP2C19 1913/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | HPGD 1510/4885CYP1A2 1283/4885CYP2C19 3070/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | HPGD 90/4885CYP1A2 664/4885CYP2C19 499/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HPGD 2153/4885CYP1A2 526/4885CYP2C19 871/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | HPGD 2513/4885CYP1A2 828/4885CYP2C19 749/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HPGD 2153/4885CYP1A2 526/4885CYP2C19 871/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HPGD 2045/4885CYP1A2 532/4885CYP2C19 799/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | HPGD 3982/4885CYP1A2 676/4885CYP2C19 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.